AI assistant
Adaptimmune Therapeutics PLC — Director's Dealing 2022
Jan 14, 2022
34721_dirs_2022-01-13_6044418d-2b8f-4e56-9a86-49dd9749ce92.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2022-01-12
Reporting Person: Wood Gavin (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-12 | Option to purchase Ordinary Shares | $0.60 | A | 1407072 | Acquired | 2032-01-12 | Ordinary Shares (1407072) | Direct |
| 2022-01-12 | Option to purchase Ordinary Shares | $0.0014 | A | 314256 | Acquired | 2032-01-12 | Ordinary Shares (314256) | Direct |
Footnotes
F1: The exercise price was converted from GBP0.44 based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F2: Exercisable as to 351,768 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the twelfth of each
month from February 12, 2023 through December 12, 2025 and 29,454 Ordinary Shares on January 12, 2026.
F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F4: Exercisable as to 78,564 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026.